In dogs, 300
Hemangiosarcoma from the dog enrolled in the metronomic study.
Light exposure decreased efficacy (MTD is that satraplatin given metronomically to dogs with currently one dog with a hemangiosarcoma is enrolled satraplatin in cats 400 be uniquely suited to C
4.375ng/ml
Results (cont.) The drug was well tolerated with good quality of life B
400
Neutrophil Nadir
Survival 10 10 20 15 30 25 2000 3000 6000 1000 0.2 0.4 0.6 0.8 1.0
Dose limiting toxicity was neutropenia (n=6, corr. w/AUC fig.3) GI toxicity was rare and usually only Grade 1 or 2

Background
The difference in satraplatin from other platinum drugs like cisplatin and carboplatin comes from its structure. It is a Pt(II) compound instead of a Pt(IV) which modifies its DNA adduct profile causing it to be more lipophilic and stable in an aqueous environment. These properties allow oral administration.

Tumors resistant to other platinum drugs are not necessarily cross-resistant to satraplatin, making the drug attractive for refractory cancers.

Satraplatin has been shown to decrease stat3 signaling which is involved in angiogenesis, suggesting that this drug may be uniquely suited to metronomic, anti-angiogenic chemotherapy.

With metronomic chemotherapy, our goal is different from standard administration in that the endpoint is not rapid tumor regression, but a stabilization of tumor size with minimal toxic side effects. The principal target is the endothelial cell rather than the tumor itself. By using this approach, the animal may have increased survival time and a better quality of life during treatment.

Results
MTD: The drug was well tolerated with good quality of life of the animal. Efficacy may be comparable to other platinum drugs.
Metronomic: Currently one patient enrolled in the trial and plan to have a minimum of 10 dogs to complete the study.

In vitro: Satraplatin is highly light-sensitive. Duration of drug exposure may be more important than concentration.

Future Directions
- Complete metronomic clinical trial
- Satraplatin as a radiosensitizer
- Satraplatin in cats
- Investigate STAT3 inhibition by satraplatin

Acknowledgements
Student supported by Merck-Merial. Drug provided by GPC Biotech, Inc. Special thanks to Mary Cockrell for assistance with cell culture, and to Dr. Armando Villamil for statistical support.